Jul. 23 at 12:50 AM
$WVE two underpriced shots in
$10 Billion+ TAMs for each drug : AATD (WVE-006)+ INHBE (WVE-007):
1) AATD — WVE-006, and Wave owns 100% of it
GSK handed WVE-006 back in Feb ’26, pre-data. Wave kept the
$30M already banked and now owns all the economics. Published data shows RNA editing producing functional M-AAT protein in humans — first-in-class GalNAc RNA editing, and on the disclosed profile a credible potential best-in-class entrant.
TAM: ~200,000 severe-deficiency patients in the US. Standard of care is lifelong weekly IV augmentation — a chronic, high-priced franchise a durable editor could displace. Multi-billion opportunity; bulls argue considerably more on full penetration.
Near-term swing: FDA accelerated-approval feedback, mid-2026. AA granted = a far faster path. Dominant binary in the name.
Caveat: MZ-like phenotype is a PD surrogate, not a validated endpoint, and Wave trails Beam on absolute AAT. AA feedback is the gate.
2) INHBE — the March capitulation was a misread
The market dumped WVE-007 in March on “disappointing” fat-loss numbers. Look at who was dosed: a low-visceral-fat cohort. INHBE silencing works by lowering visceral fat — dosing patients who didn’t have much of it, then calling the mechanism a failure, is a category error.
And Wave isn’t standing still — four cohorts now expanding: GLP-1 add-on, plus monotherapy in high-BMI patients with and without diabetes and MASH. That’s one mechanism aimed at three of the largest markets in medicine — obesity (projected ~
$100B+ by the early 2030s), MASH (~
$20–35B), T2D/metabolic (~
$100B+). These populations overlap heavily, so you don’t add them up. The point is the opposite: INHBE targets the visceral adiposity and insulin resistance sitting underneath all three, which is exactly why the cohort design fans out this way. One mechanism, multiple large addressable markets.
Meanwhile
$ARWR runs the same target, same modality, months ahead — the cleanest leading indicator available:
• ECO 2026 — Activin E elevated in obesity/T2DM, tracks insulin resistance, BMI, liver fat
• EASL 2026 — ~85% knockdown, liver-fat reduction, clean safety, and enhanced VAT + liver-fat reduction on top of tirzepatide
That last point is the thesis. ARWR’s data supports INHBE in MASH and diabetes, and positions it as a GLP-1 add-on and maintenance agent, not a competitor. Different value proposition: GLP-1s drive scale weight down but take muscle with them. INHBE targets visceral fat — the metabolically dangerous depot. Healthy weight loss, and something to hold the line when patients come off GLP-1s — where rebound is the unsolved problem in the category.
Caveats, straight: ARWR’s validation is target-level, not 007-specific — Wave must clear its own bar with its own molecule. ARWR is ahead on disclosed INHBE data, so Wave differentiates on magnitude, dosing, or muscle-sparing, not on being first. And those market figures are third-party projections with wide dispersion — order of magnitude, not gospel.
Rest of the stack: WVE-N531 (DMD) NDA 2026 · GSK 8-program engine, fully funded, up to ~
$2.8B milestones, non-dilutive · ~
$485M net cash, runway into 3Q 2028, positive EV.
Catalysts: mid-2026 WVE-006 AA feedback → 2026 N531 NDA → ~early 2027 WVE-007 higher-BMI Ph2a.
The setup, plainly: ~
$485M in the bank and three shots on goal inside 12 months — an AATD asset Wave now owns outright that a partner returned before the data matured, a DMD filing, and a metabolic program the market wrote off in March on a cohort that couldn’t have shown the effect, now expanding into four cohorts across obesity, diabetes and MASH while a competitor de-risks the mechanism in public at their expense. The market is paying for roughly one of these. It doesn’t need all three. 006 in mid-2026 is the re-rate — that’s the date on the calendar.
Long: Not advice — DYOR.
